Abstract
Ofatumumab is a new active substance indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS) with active disease defined by clinical or imaging features. It is a fully human anti-CD20 monoclonal antibody with a monthly dose of 20 mg (after the initial dosing regimen).
The advantage is a subcutaneous application by autoinjector without the need for premedication. Distribution in the body occurs through the lymphatic system, leading to higher concentrations in the lymph nodes, where B and T lymphocytes interact and represent a reservoir of autoreactive lymphocytes in MS.
Ofatumumab has been shown to be superior to teriflunomide in the reduction of relapses, MRI lesions and confirmed progression of disability in ASCLEPIOS I and II clinical trials. At the same time, a favorable safety profile was confirmed and systemic injection reactions were comparable to placebo injections, except for the 1st dose